SparingVision to Highlight Progress of its lead Gene Independent Gene Therapy Programs SPVN06 and SPVN20 at ESGCT Congress

SparingVision to Highlight Progress of its lead Gene Independent Gene Therapy Programs SPVN06 and SPVN20 at ESGCT Congress Paris, October 3, 2022 – SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, announces today that it will be presenting data on its two lead gene-independent assets, SPVN06 and SPVN20, at the European Society of Gene and Cell Therapies (ESGCT)-29th Congress to be held from 11-14 October in Edinburgh, UK. More information below: Poster Presentation: AAV delivery of G protein gated K+ channel increases cone-mediated vision in the rd10 mouse model of Retinitis Pigmentosa Date and Time: 12th October, poster #P219 Presenter: Dr. Hanen Khabou Room: Cromdale Hall, level -2. Poster Presentation: Gene-independent strategies for cone preservation in inherited rod-cone dystrophies Date and Time: 12th October, poster #P225 Presenter: Laure Blouin Room: Cromdale Hall, level -2. Poster Presentation: Development and qualification of a relative potency assay for SPVN06, a recombinant AAV vector for the treatment of inherited retinal disorders Date and Time: 12th October, poster #P347 Presenter: Charles River in collaboration with SparingVision Room: Cromdale Hall, level -2. Poster Presentation: Nonclinical safety and pharmacokinetic assessment of SPVN06, an AAV-based gene therapy for the treatment of rod-cone dystrophies Date and Time: 13th October, poster #P228 Presenter: Dr. Anne-Sophie Gautron Room: Cromdale Hall, level -2. **ENDS**

The release as fetched from its publisher. sparingvision.com ↗